Such a combination is lazertinib combined with amivantamab, an EGFR-MET bispecific antibody, which exhibited outstanding results both with and without chemotherapy in osimertinib-resistant NSCLC patients.816,817. Here, EGFR is linked to non-small cell lung carcinoma.